Spyre Therapeutics Inc. (SYRE) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Spyre Therapeutics Inc. (SYRE) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh money.
How SYRE Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $4.00B | 0% | -5.2% | -$155.2M | -$169.3M | -25.2% |
| FY 2024 | $4.00B | 0% | -5.2% | -$208.0M | -$157.4M | -35.1% |
| FY 2023 | $886.0K | 44% | -27348% | -$338.8M | -$99.9M | -5.6% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring SYRE)
- ✓Live walkthrough of SYRE's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
SYRE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +17.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SYRE today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SYRE. Explore sector supply chains on /butterfly.
SYRE Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Spyre Therapeutics Inc. (SYRE)?
In FY 2025 (10-K), SYRE converted $4.0B of revenue into a 0% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).